Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides

NEXT STORY
Inovalon and Homecare Homebase Announce Multi-Year Exclusive Agreement
PREV STORY
Respiratory Monitoring Devices Global Market Report 2021: COVID-19 Implications And Growth To 2030
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

author_avatar
NASDAQ Market News

OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®

Amsterdam, March 12-14, 2018 NANTES, France, Feb. 28, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics ...

author_avatar
NASDAQ Market News

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

author_avatar
NASDAQ Market News